Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Phase 3

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

NCT07430956 · tracked via the Priya Life Science USA tracker
Phase
Phase 3
Started
2026-04-03
Last updated
2026-11-10

Condition(s) studied

Atrial Fibrillation (AF)

Investigational drug(s) / intervention(s)

REGN7508 →REGN9933 →Placebo

REGN7508: Administered per the protocol

REGN9933: Administered per the protocol

Placebo: Administered per the protocol

Study summary

This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly. When this happens, blood cannot move smoothly through the heart; it can slow down or pool in one spot, which can lead to the formation of blood clots.

REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the study is to see how effective and safe REGN7508 and REGN9933, individually, are in preventing ischemic stroke or systemic embolism in people with atrial fibrillation who cannot or may choose to not take blood thinners.

The study is looking at several other research questions, including:

* What side effects may happen from taking REGN7508 or REGN9933
* How well does REGN7508 or REGN9933 lower the risk of having an ischemic stroke and/or systemic embolism compared to the placebo
* How well does REGN7508 or REGN9933 lower the risk of having a major health problem affecting heart and blood circulation compared to placebo
* How well does REGN7508 or REGN9933 lower the risk of death compared to placebo
* How much REGN7508 or REGN9933 is in the blood at different times
* Whether the body makes antibodies against REGN7508 or REGN9933 (which could make the study drugs less effective or could lead to side effects)

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Key Inclusion Criteria: 1. Has AF or flutter (paroxysmal or persistent), not considered to be secondary to a reversible cause 2. At moderate to high risk for stroke defined as: 1. CHA2DS2-VA \[C: Congestive heart failure; H: Hypertension; A2: Age ≥75 years (double points); D: Diabetes mellitus; S2: Stroke or TIA or Systemic embolism (double points); V: Vascular disease; A: Age 65-74 years\] score ≥4 OR 2. CHA2DS2-VA score of 3 AND at least 1 enrichment criteria as described in the protocol 3. Shared decision making between the participant and provider determining that the bleeding risk of Oral Anticoagulant (OAC) therapy outweighs the benefits, making the participant unsuitable for OAC therapy as described in the protocol Key Exclusion Criteria: 1. Has a mechanical heart valve prosthesis (Note: transcatheter aortic valve replacement is not an exclusion) 2. Had an ischemic stroke within 2 days prior to randomization 3. Has persistent, uncontrolled hypertension (per investigator's discretion) 4. Has a history of Central Nervous System (CNS) bleeding within 30 days prior to randomization 5. Has a life expectancy less than 12 months 6. Has participated in a prior Factor XI (FXI) inhibitor study Note: Other protocol-defined Inclusion/ Exclusion criteria apply

Primary outcome measure(s)

  • Time to first occurrence of ischemic stroke or systemic embolism — Up to 36 months
  • Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding — Up to 36 months

Trial sites (45)

FacilityCityRegionStatus
SEC Clinical Research Dothan Alabama Recruiting
Sun City Clinical Research Glendale Arizona Recruiting
Arkansas Cardiology P.A. Little Rock Arkansas Recruiting
Mission Cardiovascular Research Institute Fremont California Recruiting
National Institute of California Heart and Vein Specialists Huntington Beach California Recruiting
Profound Research LLC at San Diego Cardiovascular Associates La Jolla California Recruiting
Valley Clinical Trials, LLC dba Flourish Research Northridge California Recruiting
Profound Research LLC at Southern California Heart Specialists Pasadena California Recruiting
FOMAT - Comprehensive Cardiovascular Care Santa Maria California Recruiting
Cardiology Associates Medical Group Ventura California Recruiting
Interventional Cardiology Medical Group West Hills California Recruiting
East Coast Institute for Research, Jacksonville Jacksonville Florida Recruiting
South Florida Research Organization LLC Medley Florida Recruiting
Sec Clinical Research Pensacola Florida Recruiting
Cardiovascular Center of Sarasota Foundation for Research and Education Sarasota Florida Recruiting
Clinical Site Partners, LLC DBA Flourish Research Winter Park Florida Recruiting
Atlanta Clinical Research Centers Atlanta Georgia Recruiting
NSC Research, Inc Johns Creek Georgia Recruiting
Franciscan Physician Network, Indiana Heart Physicians Indianapolis Indiana Recruiting
Indiana Medical Research Merrillville Indiana Recruiting
Profound Research, Powers Health Medical Group - Electrophysiology Munster Indiana Recruiting
Monroe Research, LLC West Monroe Louisiana Recruiting
Profound Research, Cardiology and Vascular Associates (CAVA) - Bloomfield Hills Bloomfield Hills Michigan Recruiting
Profound Research, Millennium Cardiology Farmington Hills Michigan Recruiting
Flint Clinical Research Flint Michigan Recruiting
AA Medical Research Center (MRC) Flint Michigan Recruiting
Jackson Heart Clinic Jackson Mississippi Recruiting
Olive Branch Family Medical Center Olive Branch Mississippi Recruiting
Super Health Pharmacy Staten Island New York Recruiting
Hawthorne Health, Moose Pharmacy of Concord Concord North Carolina Recruiting
K&R Research LLC Marion Ohio Recruiting
AnMed Health Anderson South Carolina Recruiting
Monument Health Clinical Research Rapid City South Dakota Recruiting
Tennessee Center for Clinical Trials Tullahoma Tennessee Recruiting
PharmaTex Research Amarillo Texas Recruiting
PanAmerican Clinical Research Brownsville Texas Recruiting
Southwest Family Medicine Associates Dallas Texas Recruiting
East Texas Cardiology Houston Texas Recruiting
Synergy Group Medical,LLC Houston Texas Recruiting
Synergy Groups Medical Houston Texas Recruiting

+ 5 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07430956 on ClinicalTrials.gov ↗ ← All trials in the USA